TMED2 and neoplasm: Until routinely applied anticancer drug combinations are available simultaneously targeting HGF, EGF and NFE2L2 mediated pathways, inhibition of overexpressed DYNLL, TNC, NCL and TMED2 may exert anti-tumor effect on HNSCC beyond their diagnostic role.